Chugai Pharmaceutical Co Market capitalization 2024

The Chugai Pharmaceutical Co Market capitalization history

YEAR	REVENUE (undefined JPY)	GROSS MARGIN (%)	NET INCOME (undefined JPY)
2026e	1.19	58,42	396.59
2025e	1.15	60,65	372.1
2024e	1.1	63,30	346.07
2023	1.11	62,81	325.47
2022	1.26	62,19	374.43
2021	1	66,22	303
2020	0.79	65,25	214.73
2019	0.69	61,42	157.56
2018	0.58	54,66	92.49
2017	0.53	52,42	72.71
2016	0.49	49,58	53.59
2015	0.5	51,84	61.13
2014	0.46	52,71	50.98
2013	0.42	55,87	50.9
2012	0.39	57,13	48.21
2011	0.37	57,83	35.23
2010	0.38	57,20	41.43
2009	0.43	55,04	56.63
2008	0.33	61,15	39.26
2007	0.34	60,18	40.06
2006	0.33	59,19	38.42
2005	0.33	63,49	53.41
2004	0.29	62,15	34.03

Chugai Pharmaceutical Co Aktienanalyse

What does Chugai Pharmaceutical Co do?

Chugai Pharmaceutical Co Ltd is a Japanese pharmaceutical company founded in 1925. It is headquartered in Tokyo and employs over 7,500 employees worldwide. Chugai is one of the largest pharmaceutical companies in Japan and has become a global company with a strong research and development department in recent decades. The business model of Chugai is based on the development and production of drugs for various medical conditions, with a focus on cancer therapy. However, Chugai also has drugs for other medical conditions in its portfolio, such as rheumatism, asthma, and diabetes. The company specializes in research and development of biotechnological therapeutics and has focused on the study of biological agents. Chugai's goal is to improve people's lives and enhance patient care. Chugai is divided into several business units, each focusing on different areas of therapy. One of these areas is oncology. Chugai has a strong range of oncology products, for which it is a market leader in Japan. These include Avastin, an anti-angiogenesis drug for the treatment of colorectal, breast, lung, and kidney cancer, as well as Herceptin for the treatment of breast and gastric cancer, and Tarceva for treating bronchial carcinomas. Another important business area of Chugai is rheumatology. Here, Chugai offers various products such as Actemra, a monoclonal antibody against the interleukin-6 receptor used in rheumatoid arthritis, as well as Rituxan, an antibody against the CD20 antigen used in the treatment of lymphomas. In addition to drug development and manufacturing, Chugai also conducts research and development in the field of diagnostics. This is an important complement to the company's therapeutic portfolio. Chugai develops diagnostics to improve disease diagnosis. Another important area of Chugai is the outsourcing of research and development services. Chugai collaborates with many international pharmaceutical companies, offering its expertise and infrastructure in the development of new drugs. Chugai Pharmaceuticals is a significant player in global healthcare and aims to establish itself as a leading company in biological and cellular preparation research. The company invests significant resources in the exploration of new technologies to ensure sustainable therapy options. Chugai Pharmaceuticals has built a strong presence in the global market in recent years and will continue to play an important role in the future. Chugai Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring Chugai Pharmaceutical Co's Market Capitalization

Chugai Pharmaceutical Co's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Chugai Pharmaceutical Co's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Chugai Pharmaceutical Co's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Chugai Pharmaceutical Co’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Chugai Pharmaceutical Co Stock

What is the current Chugai Pharmaceutical Co market capitalization?

The current market capitalization of Chugai Pharmaceutical Co is 8.1 T JPY.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Chugai Pharmaceutical Co.

How has the market capitalization of Chugai Pharmaceutical Co developed in recent years?

The market capitalization of Chugai Pharmaceutical Co has increased/decreased by 37.75% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Chugai Pharmaceutical Co?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Chugai Pharmaceutical Co?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Chugai Pharmaceutical Co have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Chugai Pharmaceutical Co pay?

Over the past 12 months, Chugai Pharmaceutical Co paid a dividend of 80 JPY . This corresponds to a dividend yield of about 1.63 %. For the coming 12 months, Chugai Pharmaceutical Co is expected to pay a dividend of 93.2 JPY.

What is the dividend yield of Chugai Pharmaceutical Co?

The current dividend yield of Chugai Pharmaceutical Co is 1.63 %.

When does Chugai Pharmaceutical Co pay dividends?

Chugai Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of July, January, July, January.

How secure is the dividend of Chugai Pharmaceutical Co?

Chugai Pharmaceutical Co paid dividends every year for the past 23 years.

What is the dividend of Chugai Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 93.2 JPY are expected. This corresponds to a dividend yield of 1.89 %.

In which sector is Chugai Pharmaceutical Co located?

Chugai Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Chugai Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Chugai Pharmaceutical Co from 3/1/2025 amounting to 41 JPY, you needed to have the stock in your portfolio before the ex-date on 12/27/2024.

When did Chugai Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 3/1/2025.

What was the dividend of Chugai Pharmaceutical Co in the year 2023?

In the year 2023, Chugai Pharmaceutical Co distributed 78 JPY as dividends.

In which currency does Chugai Pharmaceutical Co pay out the dividend?

The dividends of Chugai Pharmaceutical Co are distributed in JPY.